Lineage Cell Therapeutics Inc. — Director's Dealing 2016

Apr 12, 2016

F ORM 4
---------------	--

[ ] Check this box if no longer subject to Section 16. Form 4 or continue. See Instruction 1(b).

FORM 4 Washington, D.C. 20549

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Form 5 obligations may UNITED STATES SECURITIES AND EXCHANGE COMMISSION STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
		(Check all applicable)
WEST MICHAEL D	BIOTIME INC [ BTX ]
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	__ X __ Director _____ 10% Owner
		__ X __ Officer (give title below) _____ Other (specify below)
1010 ATLANTIC AVENUE, SUITE 102	4/7/2016	Co-Chief Executive Officer
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form:	7. Nature of Indirect Beneficial
			Code	V	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Shares, no par value								875987 (1)	D

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate 2. Security Conversion (Instr. 3) or Exercise Price of Derivative		3. Trans. Date		3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)
Option to Purchase Common Shares	\$3.16	4/7/2016		A		175000		(2)	4/6/2026	Common Shares	175000	\$0.00	175000	D
Restricted Stock Units	(3)	4/7/2016		A		25000		(4)	(4)	Common Shares	25000	\$0.00	25000	D
Option to Purchase Common Shares	\$3.51							(5)	7/9/2025	Common Shares	200000		200000	D
Option to Purchase Common Shares	\$3.51							(6)	3/19/2021	Common Shares	200000		200000	D
Option to Purchase Common Shares	\$4.22							(7)	2/19/2020	Common Shares	200000		200000	D

Explanation of Responses:

( 1) Does not include shares that may be acquired upon the exercise of certain stock options.

( 2) One quarter of the options shall vest upon the completion of 12 months of continuous employment from the date of grant and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

( 3) Grant of restricted stock units under the BioTime 2012 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share.

( 4) One quarter of the restricted stock units shall vest upon the completion of 12 months of continuous employment from the date of grant and the balance shall vest in twelve equal quarterly installments upon completion of each quarter of continuous employment.

( 5) One quarter of the options vested on March 2, 2016 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

( 6) 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after March 20, 2014.

( 7) 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after January 1, 2013.

Reporting Owners

Reporting Owner Name / Address			Relationships
	Director	10% OwnerOfficer		Other
WEST MICHAEL D 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA, CA 94501	X		Co-Chief Executive Officer

Signatures

/s/ Michael D. West	4/11/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.